{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:48:49Z","timestamp":1780962529001,"version":"3.54.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/cid\/ciaa1167","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T19:28:59Z","timestamp":1596569339000},"source":"Crossref","is-referenced-by-count":1,"title":["Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?"],"prefix":"10.1093","author":[{"given":"Chia Siang","family":"Kow","sequence":"first","affiliation":[{"name":"School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shahzad","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"2020092409043160000_CIT0001","doi-asserted-by":"crossref","first-page":"ciaa819","DOI":"10.1093\/cid\/ciaa819","article-title":"ACE inhibitors\/ARB use and COVID-19. Time to change practice or keep gathering data? [published online ahead of print, 2020 Jul 4]","author":"de Feria","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020092409043160000_CIT0002","doi-asserted-by":"crossref","first-page":"pvaa064","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. [published online ahead of print, 2020 Jun 15]","author":"Grover","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2020092409043160000_CIT0003","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"2020092409043160000_CIT0004","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2020.05.052","article-title":"Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis","volume":"81","author":"Pirola","year":"2020","journal-title":"J Infect"},{"key":"2020092409043160000_CIT0005","doi-asserted-by":"crossref","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"2020092409043160000_CIT0006","first-page":"pvaa074","article-title":"Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis [published online ahead of print, 2020 Jul 16]","author":"Greco","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2020092409043160000_CIT0007","article-title":"A meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19 [published online ahead of print, 2020 Jun 2]","author":"Usman","year":"2020","journal-title":"Am J Cardiol"},{"key":"2020092409043160000_CIT0008","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.dsx.2020.06.047","article-title":"The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"14","author":"Pranata","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2020092409043160000_CIT0009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40256-020-00406-0","article-title":"Cardiovascular disease and use of renin-angiotensin system inhibitors in COVID-19","volume":"20","author":"Kow","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"2020092409043160000_CIT0010","doi-asserted-by":"crossref","first-page":"pvaa062","DOI":"10.1093\/ehjcvp\/pvaa062","article-title":"Association between renin-angiotensin system inhibitors and COVID-19 complications [published online ahead of print, 2020 Jun 12]","author":"Liabeuf","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1167\/33787818\/ciaa1167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1167\/33787818\/ciaa1167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T13:05:31Z","timestamp":1600952731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa1167\/5889984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1167","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"article-number":"ciaa1167"}}